Central Drugs Standard Control has agreed to use a Russian Sputnik V vaccine for emergency usage in India from the Subject Expert Committee of CDSCO.
Sputnik V will become India’s third vaccine after Covidshield and Covaxin. Sputnik will be rollout third trial successfully in Russia. The vaccine has been funded by the Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund.
Sputnik V uses a cold type- virus to deliver a small part of the coronavirus spike proteins to the body and help to develop an immune response to it.
However, The Russian Sputnik V Vaccine will boost India’s capability to take its vaccination drive forward. India has two approved vaccines, Covishield and Covaxin.
The major difference in Sputnik uses two different vectors in within 21 day apart unlike other vaccines. This will make the immune response stronger to confront the corona virus.